Caris Life Sciences

Caris Life Sciences Caris Life Sciences delivers technologies to revolutionize healthcare with market-leading profiling

Caris Life Sciences® is the leading next-generation TechBio company and precision medicine pioneer that is actively developing and delivering innovative solutions to revolutionize healthcare and improve the human condition. Through comprehensive molecular profiling (Whole Exome and Whole Transcriptome Sequencing) and the application of advanced artificial intelligence (AI) and machine learning al

gorithms, Caris has created the large-scale, clinico-genomic database and computing capability needed to analyze and unravel the molecular complexity of disease. This convergence of sequencing power, big data and AI technologies provides an unmatched platform to deliver the next-generation of precision medicine tools for early detection, diagnosis, monitoring, therapy selection and drug development.

A breast cancer diagnosis can bring uncertainty about what comes next, especially regarding the risk of recurrence.Caris...
06/05/2026

A breast cancer diagnosis can bring uncertainty about what comes next, especially regarding the risk of recurrence.

Caris MI Clarity™ helps provide insight into both early and late distant recurrence risk from the very beginning using information from your existing pathology and clinical data.

Ask your doctor if MI Clarity is right for you: https://ow.ly/KURs50Z7NWX

Discover what’s next in precision oncology at the UK Oncology Forum 2026. Join Caris Life Sciences at Stand G38 to explo...
06/04/2026

Discover what’s next in precision oncology at the UK Oncology Forum 2026. Join Caris Life Sciences at Stand G38 to explore our latest product offerings and comprehensive molecular profiling advancements designed to support more informed cancer care decisions.

Connect with our team to learn how these innovations can support your work — schedule an onsite meeting to continue the conversation: https://ow.ly/8NIx50Z7LKg

MI Cancer Seek® is the first and only simultaneous Whole Exome Sequencing (WES) and Whole Transcriptome Sequencing (WTS)...
06/03/2026

MI Cancer Seek® is the first and only simultaneous Whole Exome Sequencing (WES) and Whole Transcriptome Sequencing (WTS)-based assay with FDA-approved CDx indications for molecular profiling of solid tumors. MI Cancer Seek is available for adult and pediatric patients (ages 1+).

Learn more: https://bit.ly/4lyGNTR

Join the conversation with Caris Chief Medical Officer George Sledge Jr., MD, as he takes part in the AI in Action: Real...
06/01/2026

Join the conversation with Caris Chief Medical Officer George Sledge Jr., MD, as he takes part in the AI in Action: Real-World Healthcare AI Deployments webinar. During his session "From Discovery to Delivery: How AI Is Reshaping Biotech,” gain insights into the evolving role of AI in life sciences, the challenges of integrating AI into research and clinical workflows and what the next wave of AI-driven innovation could mean for the future of healthcare. Register here: https://ow.ly/1neo50Z6iLP

Connect with Caris at ! Meet with our team, hear the latest information on our current product offerings and learn abou...
05/31/2026

Connect with Caris at ! Meet with our team, hear the latest information on our current product offerings and learn about the most advanced approach to precision medicine. Visit booth 27059. https://bit.ly/4ecyVWB

Myeloid malignancies are genetically complex and often require multiple assays. Caris ChromoSeq brings the full genomic ...
05/31/2026

Myeloid malignancies are genetically complex and often require multiple assays. Caris
ChromoSeq brings the full genomic landscape into one high-coverage Whole Genome
Sequencing (WGS) test, supporting clearer diagnosis and risk stratification in a single report. Learn more during : https://bit.ly/4ecyVWB

Caris’ strong presence at demonstrates the clinical value of comprehensive molecular profiling and our commitment to t...
05/31/2026

Caris’ strong presence at demonstrates the clinical value of comprehensive molecular profiling and our commitment to transforming lives through research. Discover more about our groundbreaking studies. https://bit.ly/4ecyVWB

The American Society of Clinical Oncology (ASCO) Annual Meeting is underway. Stop by Booth 27059 to meet with the Caris ...
05/30/2026

The American Society of Clinical Oncology (ASCO) Annual Meeting is underway. Stop by Booth 27059 to meet with the Caris Life Sciences team and explore how our molecular profiling and AI-driven insights are shaping the future of oncology. We're ready to connect. https://bit.ly/4ecyVWB

05/28/2026

Join us at the American Society of Clinical Oncology (ASCO) Annual Meeting to discover MI Cancer Seek®, the first and only simultaneous Whole Exome Sequencing (WES) and Whole Transcriptome Sequencing (WTS)-based assay with FDA-approved companion diagnostic (CDx) indications for molecular profiling of solid tumors.

Learn how combined DNA and RNA insights support precision oncology for adult and pediatric (ages 1+) patients.

Visit us at booth #27059 or schedule an on-site meeting: https://ow.ly/SNjq50Z1FTx

The American Society of Clinical Oncology (ASCO) Annual Meeting is almost here. Join us at booth 27059 to discover our l...
05/27/2026

The American Society of Clinical Oncology (ASCO) Annual Meeting is almost here. Join us at booth 27059 to discover our latest advances in precision medicine, explore newly launched products and see how Caris innovation and collaboration are helping shape the future of oncology. Schedule an on-site meeting: https://ow.ly/6RZN50Z2Xay

Address

-
Irving, TX
75039

Opening Hours

Monday 7am - 7pm
Tuesday 7am - 7pm
Wednesday 7am - 7pm
Thursday 7am - 7pm
Friday 7am - 7pm

Telephone

+18889798669

Website

Alerts

Be the first to know and let us send you an email when Caris Life Sciences posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Featured

Share

Category